Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1)

References

• Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. Arab J Gastroenterol. 2010;11(3):174–179.
   Google Scholar
• Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2014;61(1):191–199. doi:10.1002/hep.27388
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844. doi:10.1038/nrd2130
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res. 2013;43(2):147–154. doi:10.1111/j.1872-034X.2012.01113.x
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Eggelpoël M-J B-V, Chettouh H, Fartoux L, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 2012;57(1):108–115. doi:10.1016/j.jhep.2012.02.019
   PubMed Web of Science ®Google Scholar
• Ezzoukhry Z, Louandre C, Trécherel E, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Interna J Cancer. 2012;131(12):2961–2969. doi:10.1002/ijc.27604
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4(1):1–11. doi:10.1186/1756-8722-4-30
   PubMedGoogle Scholar
• Mazumdar J, O’brien WT, Johnson RS, et al. O2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol. 2010;12(10):1007–1013. doi:10.1038/ncb2102
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–1983. e1911. doi:10.1053/j.gastro.2008.08.008
   PubMed Web of Science ®Google Scholar
• Hernandez–Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–527. doi:10.1053/j.gastro.2013.01.002
   PubMed Web of Science ®Google Scholar
• Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Med. 2012;18(4):521–528. doi:10.1038/nm.2713
   PubMed Web of Science ®Google Scholar
• Huang X-Y, A-W K, Shi G-M, et al. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology. 2013;57(6):2235–2247. doi:10.1002/hep.26255
   PubMed Web of Science ®Google Scholar
• Castillo J, Erroba E, Perugorría M, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006;66(12):6129–6138. doi:10.1158/0008-5472.CAN-06-0404
   PubMed Web of Science ®Google Scholar
• Shen Y, Ou D, Hsu C, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013;108(1):72–81. doi:10.1038/bjc.2012.559
   PubMed Web of Science ®Google Scholar
• Shimizu S, Takehara T, Hikita H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Interna J Cancer. 2012;131(3):548–557. doi:10.1002/ijc.26374
   PubMed Web of Science ®Google Scholar
• Liang Y, Zheng T, Song R, et al. Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma. Hepatology. 2013;57(5):1847–1857. doi:10.1002/hep.26224
   PubMed Web of Science ®Google Scholar
• Xin H-W, Ambe CM, Hari DM, et al. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 2013;62(12):1777–1786. doi:10.1136/gutjnl-2012-303261
   PubMed Web of Science ®Google Scholar
• Shen Y-C, Lin -Z-Z, Hsu C-H, Hsu C, Shao -Y-Y, Cheng A-L. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer. 2013;2(3–4):345–364. doi:10.1159/000343850
   PubMed Web of Science ®Google Scholar
• Faber KN, Müller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Delivery Rev. 2003;55(1):107–124. doi:10.1016/S0169-409X(02)00173-4
   PubMed Web of Science ®Google Scholar
• Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–560. doi:10.1038/nrd4626
   PubMed Web of Science ®Google Scholar
• Lozano E, Herraez E, Briz O, et al. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int. 2013;2013:1–13. doi:10.1155/2013/692071
   Web of Science ®Google Scholar
• Herraez E, Lozano E, Macias RI, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58(3):1065–1073. doi:10.1002/hep.26425
   PubMed Web of Science ®Google Scholar
• Ferraris P, Chandra PK, Panigrahi R, et al. Cellular mechanism for impaired hepatitis C virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-λ expression. Am J Pathol. 2016;186(4):938–951. doi:10.1016/j.ajpath.2015.11.027
   PubMed Web of Science ®Google Scholar
• Wilkens L, Hammer C, Glombitza S, Müller D-E. Hepatocellular and cholangiolar carcinoma-derived cell lines reveal distinct sets of chromosomal imbalances. Pathobiology. 2012;79(3):115–126. doi:10.1159/000334100
   PubMed Web of Science ®Google Scholar
• Bao L, Haque A, Jackson K, et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 2011;178(2):838–852. doi:10.1016/j.ajpath.2010.10.029
   PubMed Web of Science ®Google Scholar
• Swift B, Nebot N, Lee JK, et al. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos. 2013;41(6):1179–1186. doi:10.1124/dmd.112.048181
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–1431. doi:10.1172/JCI30558
   PubMed Web of Science ®Google Scholar
• Zu Schwabedissen HE M, Begunk R, Hussner J, et al. Cell-specific expression of uptake transporters? a potential approach for cardiovascular drug delivery devices. Mol Pharmaceut. 2014;11(3):665–672. doi:10.1021/mp400245g
   PubMed Web of Science ®Google Scholar
• Savić R, He X, Fiel I, Schuchman EH. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One. 2013;8(5):e65620. doi:10.1371/journal.pone.0065620
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J clin oncol. 2006;24(26):4293–4300. doi:10.1200/JCO.2005.01.3441
   PubMed Web of Science ®Google Scholar
• Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspect Med. 2013;34(2–3):529–547. doi:10.1016/j.mam.2012.05.007
   PubMed Web of Science ®Google Scholar
• Okabe M, Unno M, Harigae H, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun. 2005;333(3):754–762. doi:10.1016/j.bbrc.2005.05.174
   PubMed Web of Science ®Google Scholar
• Namisaki T, Schaeffeler E, Fukui H, et al. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos. 2014;42(12):2033–2040. doi:10.1124/dmd.114.059832
   PubMed Web of Science ®Google Scholar
• Heise M, Lautem A, Knapstein J, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer. 2012;12(1):1–10. doi:10.1186/1471-2407-12-109
   PubMedGoogle Scholar
• Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015;45(6):609–623. doi:10.1111/eci.12441
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-1377
   PubMed Web of Science ®Google Scholar
• Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Invest Drugs. 2010;19(5):615–629. doi:10.1517/13543781003767418
   PubMed Web of Science ®Google Scholar
• Carr BI, D’Alessandro R, Refolo MG, et al. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol. 2013;228(6):1344–1350. doi:10.1002/jcp.24291
   PubMed Web of Science ®Google Scholar
• Chen K-F, Chen H-L, Tai W-T, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011;337(1):155–161. doi:10.1124/jpet.110.175786
   PubMed Web of Science ®Google Scholar
• Marin JJ, Macias RI, Monte MJ, et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers. 2020;12(6):1663. doi:10.3390/cancers12061663
   PubMed Web of Science ®Google Scholar
• Marin JJ, Romero MR, Herraez E, et al. Mechanisms of pharmacoresistance in hepatocellular carcinoma: new drugs but old problems. Paper presented at: Seminars in Liver Disease 2021.
   Google Scholar
• Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Cancer Res. 2015;75(12):2510–2519. doi:10.1158/0008-5472.CAN-14-3687
   PubMed Web of Science ®Google Scholar
• Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res. 2015;21(13):2916–2923. doi:10.1158/1078-0432.CCR-14-1213
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847–8857. doi:10.1158/0008-5472.CAN-06-0769
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Terada T, Katsura T, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet. 2010;25(2):190–199. doi:10.2133/dmpk.25.190
   PubMed Web of Science ®Google Scholar
• Lin R, Li X, Li J, et al. Long-term cisplatin exposure promotes methylation of the OCT1 gene in human esophageal cancer cells. Dig Dis Sci. 2013;58(3):694–698. doi:10.1007/s10620-012-2424-9
   PubMed Web of Science ®Google Scholar
• Herraez E, Al-Abdulla R, Soto M, et al. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors. Biochem Pharmacol. 2023;217:115812. doi:10.1016/j.bcp.2023.115812
   PubMed Web of Science ®Google Scholar
• Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem. 2019;26(7):1224–1250. doi:10.2174/0929867325666180105103637
   PubMed Web of Science ®Google Scholar
• Saunders NA, Simpson F, Thompson EW, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012;4(8):675–684. doi:10.1002/emmm.201101131
   PubMed Web of Science ®Google Scholar
• Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Human Gene. 2007;52(2):117–122. doi:10.1007/s10038-006-0087-0
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013;86(5):666–678. doi:10.1016/j.bcp.2013.06.019
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104(12):3739–3745. doi:10.1182/blood-2003-12-4276
   PubMed Web of Science ®Google Scholar
• Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Trans Targe Thera. 2020;5(1):87. doi:10.1038/s41392-020-0187-x
   PubMed Web of Science ®Google Scholar
• Tomonari T, Takeishi S, Taniguchi T, et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget. 2016;7(6):7207. doi:10.18632/oncotarget.6889
   PubMedGoogle Scholar
• Lozano E, Macias RI, Monte MJ, et al. Causes of hOCT1‐dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor‐selective gene therapy. Hepatology. 2019;70(4):1246–1261. doi:10.1002/hep.30656
   PubMed Web of Science ®Google Scholar